TABLE 1.
Summary of the study design, patient population and non-small cell lung cancer (NSCLC) drug used for each publication.
| References (publication year) | Clinical trial identifier | Reporting country | Study design | Total number of cluster groups | Total number of patients | Age, median (range) | Sex (M/F) | Severity of Illness/NSCLC stage | Co-morbidities | Subgroups measured | Drugs involved |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mizugaki et al. (2015) | NCT01617928 | Japan | Open-label, Phase I Study | 3 | 12 | 67 (44–73 years old) | 10M 2F | Stage IIIIB, Stage IV, Postoperative recurrence | Smoker status | Dose | Carboplatin, Paclitaxel, Veliparib |
| Huang et al. (2020) | NCT03201146 | China | Phase I Study | 3 | 12 | 53.4 (42.2–63.4 years old) | 7M 5F |
Stage IVA, Stage IVB |
Smoker status | Dose | Apatinib, Carboplatin, Pemetrexed |
| Sebastian et al. (2019) | N/A | Germany & Switzerland | Prospective, multicenter, open-label, uncontrolled phase I/IIa trial | 4 | 46 | 64.7 (SD: 10.2) | 29M 1 7F |
Stage IIIB, Stage IV | N/A | Dose | CV9201 (generated using proprietary RNActive® Technology) |
| Novello et al. (2014a) | NCT01086254 | Italy, France, Germany, Spain, United Kingdom | Phase II, randomized, open-label, non-comparative study | 2 | 119 | 58.7 (29–73 years old) | 90M 29F | Stage I, Stage III, Stage IV |
Smoker status | N/A | Cisplatin, Iniparib, Gemcitabine |
| Cappuzzo et al. (2006) | N/A | Italy | Phase II, randomized Study | 2 | 117 | 72.5 (54–81 years old) | 98M 19F | Stage IIIB, Stage IV |
N/A | Infusion Duration | Chemotherapy, Gemcitabine |
| Srinivasa et al. (2020) | N/A | India | Randomized prospective study | 2 | 36 | 57 (45–65 years old) | 33M 3F | Stage IIIA, Stage IIIB | N/A | N/A | Carboplatin, Cisplatin, Etoposide, Paclitaxel |
| Yoshioka et al. (2017) | NCT01207011 | Japan | Randomized, open-label, phase III trial | 2 | 197 | 20–75 years old | 135M 62F |
Stage IIIIB, Stage IV, Postoperative recurrence | Smoker status | N/A | Amrubicin, Docetaxel |
| Johnson et al. (2013) | NCT00257608 | United States | Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial | 2 | 743 | 64 (23–88 years old) | 389M, 354F | Stage IIIB, Stage IV, Recurrent | Smoker Status | N/A | Bevacizumab, Erlotinib (Chemotherapy prior to trial) |
| EU Clinical Trials Register. (2011) | MEK114653 (EU Clinicals Register) | France, Greece, Hungary, Italy, Netherlands, South Korea, Spain, United States | Phase II, Open-label, Multicenter, Randomized Study | 2 | 134 (4 drop out) | 61.2 (18–64 years old) | 69M, 65F | Stage IIIB, Stage IV | N/A | Crossover Phase | Docetaxel, GSK1120212 |
| Gridelli et al. (2001) | N/A | Italy | Pilot Single-Stage Phase II Study | 2 | 98 | 74 (70–82 years old) | 83M, 15F |
Stage IIIB, Stage IV | N/A | N/A | Gemcitabine, Vinorelbine |
| Martoni et al. (1991) | N/A | Italy | Phase I Trial | 4 | 24 | 60 (36–68 years old) | 24M, 0F |
Stage IIIB, Stage IV |
N/A | Dose, LVEF values |
Epirubicin |
| Sequist et al. (2013), Boehringer Ingelheim (2018a), Wu et al. (2018) | NCT00949650 (LL3) | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Malaysia, Peru, Philippines, Romania, Russia, South Korea, Taiwan, Thailand, Ukraine, United Kingdom, United States | Global, randomized, open-label phase III study | 2 | 345 | 60.3 (S.D. 10.1 years old) | 121M, 224F | Stage IIIB, Stage IV |
Smoker Status | N/A | Afatinib, Cisplatin, Pemetrexed |
| Boehringer Ingelheim, (2018a) Boehringer Ingelheim. (2018b) | NCT01121393 | China, South Korea, Thailand | Randomized, Open-label, Phase III Study | 2 | 364 | 56.4 (SD: 10.9) | 126M, 238F | Stage IIIB, Stage IV |
Smoker Status | N/A | Afatinib (BIBW2992), Cisplatin, Gemcitabine |
| Boehringer Ingelheim (2020) | NCT01466660 | Australia, Canada, China, France, Germany, Hong Kong, Ireland, Norway, Singapore, South Korea, Spain, Sweden, Taiwan, United Kingdom | Randomised, Open-label Phase IIB Trial | 2 | 319 | 62.4 (SD: 11.0) | 122M, 197F | Stage IIIB, Stage IV |
Smoker Status | N/A | Afatinib, Gefitinib |
| Hida et al. (2017) | JapicCTI-132316 (Japan Pharmaceutical Information Centre) | Japan | Phase III, Open-label, Multicenter, Randomised Trial | 2 | 207 | 60.2 (25–85 years old) | 82M, 125F |
Stage IIIIB, Stage IV, Postoperative recurrence | Smoker Status | N/A | Alectinib, Crizotinib |
| Berghmans et al. (2013) | NCT00622349 | Belgium, France, Greece, Spain | Phase III Trial | 3 | 693 | 58 (28–84 years old) | 523M,170F | Stage IIB, Stage IIIA, Stage IIIB, Stage IV | N/A | N/A | Cisplatin, Docetaxel, Gemcitabine, Ifosfamide |
| GlaxoSmithKline (2014) | NCT01362296 | France, Greece, Hungary, Italy, Netherlands, South Korea, Spain, United States | Phase II, Open-label, Multicenter, Randomised Trial | 2 | 134 | 61.2 (SD: 9.32) | 69M, 65F |
Stage IV | Smoker Status | N/A | Docetaxel, GSK1120212 (Trametinib) |
| Martoni et al. (1999) | N/A | Italy | Pilot Study | 2 | 212 | 61 (42–72 years old) | 179M, 33F | Stage IIIA, Stage IIIB, Stage IV, Recurrence | N/A | N/A | Epirubicin, cisplatinum, vinorelbine |
| Reck et al. (2015) | NCT00805194 | Austria, Belarus, Belgium, Bulgaria, China, Croatia, Czech Republic, Denmark, France, Georgia, Germany, Greece, India, Israel, Italy, Lithuania, Poland, Portugal, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Switzerland, Ukraine, United Kingdom | Randomized, Placebo-Controlled, Phase III trial | 2 | 1314 | 59.8 | 955M, 359F |
<Stage IIIB, Stage IIIB, Stage IV |
Smoker Status | N/A | Docetaxel, Nintedanib |
| Saito et al. (2003) | N/A | Japan | Parallel | 2 | 25 | 61.8 (40–79 years old) | 16M, 9F |
Stage III, Stage IV |
N/A | LVEF | Carboplatin, Docetaxel, Paclitaxel |
| Barlesi et al. (2018) | NCT02395172 | Argentina, Australia, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Hungary, Israel, Italy, Japan, Latvia, Mexico, Peru, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey, United Kingdom, and United States | Open-label, multicentre, randomised Phase III trial | 2 | 792 | 63.5 (57–69 years old) | 542M 250F |
Stage IIIB, Stage IV, Recurrent NSCLC with disease progression after previous platinum doublet treatment> |
Smoker Status | N/A | Avelumab, Docetaxel |
| Camidge et al. (2018) | NCT02737501 | Australia, Austria, Canada, Denmark, France, Germany, Hong Kong, Italy, South Korea, Luxembourg, Netherlands, Norway, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States | Open-label, multicenter, randomized, international, Phase III trial | 2 | 275 | 59 (27–89 years old) | 125M 150F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Brigatinib, Crizotinib |
| Wachters et al. (2004) | N/A | Netherlands | Randomised phase III trial | 2 | 69 | 61 (43–76 years old) | 49M 20F |
Stage IIIA, Stage IIIB Stage IV |
N/A | LVEF | Cisplatin, Epirubicin, Gemcitabine |
| Shaw et al. (2013) | NCT00932893 | Australia, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Russian Federation, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States | Phase 3, Randomized, Open-label Study | 2 | 347 | 50 (22–85 years old) | 154M 193F | Advanced | Smoker Status | N/A | Crizotinib (PF-02341066), Docetaxel, Pemetrexed |
| Solomon et al. (2014) | NCT01154140 | Australia, Austria, Belgium, Brazil, Canada, Chile, China, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Luxembourg, Mexico, Netherlands, Norway, Peru, Portugal, Russian Federation, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States | Phase 3, Randomized, Open-label Study | 2 | 343 | 53 (19–78 years old) | 131M 212F |
Advanced | Smoker Status | N/A | Crizotinib, Carboplatin, Cisplatin, Pemetrexed |
| Bonomi et al. (2000) | N/A | United States | A Phase III Study | 3 | 574 | 61.8 | 365M 209F |
Stage IIIB, Stage IV | N/A | Dose | Cisplain, Etoposide, Paclitaxel |
| Zatloukal et al. (2004) | N/A | Czech Republic | Prospective, randomized open, parallel group study | 2 | 102 | 61.5 (42–75 years old) | 69M 33F |
Stage IIIA, Stage IIIB |
N/A | N/A | Cisplatin, Vinorelbine |
| Zarogoulidis et al. (2013) | N/A | Greece | Four-arm Phase III Trial | 4 | 229 | 62.5 | 187M 37F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Bevacizumab, Carboplatin, Docetaxel, Erlotinib |
| Koch et al. (2011) | NCT00300729 | Sweden | Double-blind, placebo-controlled multicentre Phase III Trial | 2 | 316 | 65.5 (37–85 years old) | 160M 156F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Celecoxib, Chemotherapy (carboplatin/cisplatin/gemcitabine/vinorelbine) |
| Bi et al. (2019) | NCT01503385 | China | A Phase II Randomized Clinical Trial | 2 | 96 | 60 | 73M 23F |
Stage IIIA, Stage IIIB |
Smoker Status | N/A | Celecoxib, Cisplatin, Etoposide |
| Herbst et al. (2011) | NCT00130728 | 12 countries including United States | Double-blind, Placebo-Controlled, Randomised Phase 3 trial | 2 | 636 | 64.9 | 341M 295F |
N/A | Smoker Status | N/A | Bevacizumab, Erlotinib |
| Kato et al. (2018); Seto et al. (2014) | JapicCTI-111390 (Japan Pharmaceutical Information Centre) | Japan | Open-label, randomised, multicentre, Phase II Study | 2 | 152 | 67 (59–73 years old) | 56M 96F |
Stage IIIB Stage IV, Postoperative recurrence |
Smoker Status | N/A | Bevacizumab, Erlotinib |
| National Cancer Institute. (2019) | NCT00126581 | United States | A Phase II Randomized, Open label Study | 2 | 181 | 59 (32–81 years old) | 74M 107F |
Stage III, Stage IV |
Smoker Status | N/A | Carboplatin, Erlotinib, Paclitaxel |
| Stathopoulos et al. (2004) | N/A | Greece | Multicenter, randomized, phase III trial | 2 | 360 | 65 (30–84 years old) | 312M 48F |
Stage IIIA, Stage IIIB, Stage IV |
N/A | N/A | Carboplatin, Paclitaxel, Vinorelbine |
| Valdivieso et al. (1984) | N/A | United States | Prospective, randomised study | 2 | 100 | 56.5 (33–78 years old) | 79M 21F |
N/A | Biopsy | Weekly VS. once every 3 weeks doxorubicin | Cisplatin, Cyclo-phosphamide, Doxorubicin, Ftorafur |
| Baggstrom et al. (2017a) | NCT00693992 | United States | Randomized, double-blind, placebo-controlled phase III trial | 2 | 210 | 64.9 (25–89 years old) | 117M 93F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Chemotherapy, Sunitinib |
| Paz-Ares et al. (2015) | NCT00863746 | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, South Korea, Netherlands, Pakistan, Peru, Phillippines, Poland, Russia, Singapore, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States | Phase III, randomized, double-blind, placebo-controlled trial | 2 | 703 | ≥18 years old | 395M 308F |
N/A | Smoker Status | N/A | Best supportive care, Sorafenib |
| Novello et al. (2014b) | NCT00460317 | 32 countries including Italy, Germany, Romania, Ukraine, United Kingdom, United States | Phase 3, randomized, placebo-controlled, doubleblind study | 2 | 360 | 60.8 (31–81 years old) | 295M 65F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Carboplatin, Paclitaxel, Motesanib |
| Akamatsu et al. (2018) | NCT02151981 | Australia, Canada, China, France, Germany, Hong Kong, Hungary Italy, Japan, Mexico, Netherlands, Russia, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States | Randomized, open-label, phase III clinical trial | 2 | 419 | 62.5 (20–90 years old) | 150M 269F |
N/A | Smoker Status | N/A | Carboplatin, Cisplatin, Pemetrexed, Osimertinib |
| Kosmidis et al. (2008) | N/A | Greece | Phase III Study | 2 | 452 | 63 (36–83 years old) | 378M 74F |
Stage IIIB, Stage IV |
N/A | N/A | Carboplatin, Paclitaxel, Gemcitabine |
| Reinmuth et al. (2019) | NCT02364999 | Australia, Brazil, Bulgaria, Chile, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Italy, Japan, South Korea, Malaysia, Netherlands, Philippines, Poland, Romania, Russia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United States | Multinational, double-blind, randomized, parallel-group study | 2 | 719 | 61.5 (25–87 years old) | 467M 252F |
Stage IIIB, Stage IV, Recurrent | Smoker Status | N/A | Bevacizumab, Carboplatin, Paclitaxel, PF-06439535 |
| Blumenschein et al. (2010) | NCT00094835 | United States | Multicenter, Open-label, Dose-finding, Phase IB study of motesanib | 3 | 45 | 61.3 (32–79 years old) | 29M 16F |
Stage IIIB, Stage IV |
Smoker Status | N/A | Carboplatin, Paclitaxel, Panitumumab, Motesanib |
| Choy et al. (2013) | NCT00482014 | India, United States | Open-label, Randomised Trial | 2 | 98 | 63.6 (43.7–85.2 years old) | 61M 37F |
Stage IIIA, Stage IIIB |
N/A | N/A | Carboplatin, Cisplatin Pemetrexed |
| William et al. (2007) | N/A | United States | Open-label, Phase I, Dose-escalationStudy | 4 | 21 | 52 (38–71 years old) | 13M 8F |
Stage IV | N/A | Dose | Cisplatin, Docetaxel, Motexafin gadolinium |
| Chang et al. (1993) | N/A | United States | Phase II Study | 3 | 103 | 61.3 (31–85 years old) | 70M 33F |
Stage IV | N/A | N/A | Merbarone, Piroxantrone, Taxol |
| Kubota et al. (2017) | JapicCTI-121887 (Japan Primary Registries Network) | Japan, South Korea, Hong Kong, Taiwan | Phase III, Randomized, Placebo-Controlled, Double-blind Study | 2 | 401 | 65 (Upper Quartile: 58; Lower Quartile: 70) | 288M 113F |
Stage IV, Recurrent | Smoker Status | N/A | Carboplatin, Motesanib, Paclitaxel |
| Zinner et al. (2015) | NCT00948675 | United States | Multicenter, Randomized, Open-label, US-only Phase III Trial | 2 | 361 | 65.6 (38.4–86.2 years old) | 209M 152F |
Stage IV | Smoker Status | N/A | Bevacizumab, Carboplatin, Paclitaxel Pemetrexed |
| Heigener et al. (2013) | NCT00160069 | Germany | Prospective, Multicenter, Phase II study | 3 | 128 | 63 | 83M 45F |
Stage IIIB, Stage IV | N/A | Dose, Duration of Infusion | Sagopilone |
| Jie Wang et al. (2018) | N/A | China | Randomised Controlled Trial | 2 | 128 | No mean/median (36–76 years old) | 96M 32F |
N/A | N/A | N/A | Cisplatin, Endostar, Pemetrexed |
| Eli Lilly and Company (2019a) | NCT01469000 | China, Japan, South Korea, Taiwan | Multicenter, Randomized, open-label, parallel-arm, phase II study | 2 | 191 | 61.71 (S.D.: 9.38) | 68M 123F |
Stage IV | N/A | N/A | Gefitinib, Pemetrexed |
| Douillard (2004) | N/A | Belgium, Canada, France, Germany, Italy, Spain, United States | Randomized, Double-blind, Placebo-controlled, Phase II Feasibility Study | 2 | 75 | 61.4 | 56M 19F |
Stage IIIB, Stage IV | N/A | N/A | BMS-275291, Carboplatin, Paclitaxel |
| Butts et al. (2007) | N/A | Canada, United States | Multicenter, Open-label, Randomized Phase II study | 2 | 131 | 66 (35–84 years old) | 58M 73F |
Stage IIIB Stage IV, Recurrent |
N/A | N/A | Carboplatin, Cisplatin, Cetuximab, Gemcitabine |
| Fukuda et al. (2019) | UMIN000008771 (University Hospital Medical Information Network) | Japan | Randomised Phase II Study | 2 | 40 | 78 (75–83 years old) | 23M 17F |
Stage IIIB, Stage IV, Postoperative recurrence |
Smoker Status | N/A | Bevacizumab, Pemetrexed |
| Passardi et al. (2008) | N/A | Italy | Randomized Phase II Trial | 2 | 81 | 63 (35–77 years old) | 65M 16F |
Stage IV | N/A | N/A | Docetaxel, Gemcitabine |
| Gatzemeier et al. (2004) | N/A | Canada, Italy, Germany, Netherlands, United Kingdom | Randomized, Open-label, Phase II study | 2 | 101 | 58.5 (35–76 years old) | 63M 38F |
Stage IB, Stage IIIB, Stage IV |
N/A | N/A | Cisplatin, Gemcitabine, Trastuzumab |
| Park et al. (2017) | NCT01282151 | South Korea | Open-label, Multicenter Prospective Phase III Study | 2 | 148 | 63.3 | 103M 45F |
Stage IIIB, Stage IV | Smoker Status | N/A | Cisplatin, Docetaxel, Pemetrexed |
| Movsas et al. (2005) | N/A | Canada, United States | Randomised Trial | 2 | 242 | ≥18 years old | 150M 92F |
Stage IIA, Stage IIB, Stage IIIA, Stage IIIB | N/A | N/A | Amifostine, Carboplatin, Paclitaxel |
| Jänne et al. (2014) | N/A | Canada, Germany, Spain, United States | Randomized, Double-Blind, Phase II Trial | 3 | 200 | 61.4 (27.8–87.8 years old) | 127M 68F |
Stage IIIB, Stage IV | Smoker Status | Dose | Cisplatin, Gemcitabine, LY293111 |
| Groen et al. (2011) | N/A | Netherlands | Randomized, Placebo-Controlled Phase III Study | 2 | 561 | 61 (33–84 years old) | 355M 206F |
Stage IIIB, Stage IV | N/A | N/A | Carboplatin, Celecoxib, Docetaxel |
| Currow et al. (2017) | NCT01395914 | Australia, Belarus, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Poland, Russia, Serbia, Slovenia, Spain, Ukraine | Double-blind, safety extension Phase III Study | 2 | 513 | 62.0 | 387M 126F |
Stage IIIA, Stage IIIB, Stage IV |
N/A | N/A | Anamorelin, Placebo |
| Langer et al. (2017) | NCT00789373 | Australia, Belgium, Canada, Finland, France, Germany, Greece, India, Italy, Netherlands, Poland, Portugal, Romania, Spain, Turkey, United Kingdom | Phase 3, Double-Blind, Placebo-Controlled Study | 2 | 939 | 61.3 (24.4–83.0 years old) | 577M 362F |
Stage IIIB, Stage IV | Smoker Status | N/A | Cisplatin, Pemetrexed, Placebo |
| Kotsakis et al. (2015) | NCT00620971 | Greece | A Multicenter, Randomized, Phase II study | 2 | 77 | 59 (36–77 years old) | 57M 20F |
Stage IIIB, Stage IV | Smoker Status | N/A | Bevacizumab, Cisplatin, Docetaxel, Gemcitabine, Vinorelbine |
| Eli Lilly and Company (2015) | NCT00112294 | United States | A Phase III, Randomised, Open Label Study | 2 | 676 | 64 (S.D.: 10.2) | 396M 280F |
N/A | N/A | N/A | Carboplatin, Cetuximab, Taxane (Paclitaxel/Docetaxel) |
| GlaxoSmithKline (2019) | NCT01868022 | Belgium, Denmark, Netherlands, Russia, Spain, United Kingdom, United States | Multi-arm, Non-randomized, Open-Label Phase IB Study | 9 | 65 | 66.52 (S.D.: 3.08) | 52M 13F |
Stage IIIB, Stage IV | N/A | Dose | Carboplatin, Cisplatin, Docetaxel, GSK3052230, Paclitaxel, Pemetrexed |
| Lara et al. (2016) | N/A | United States | Randomised, Phase II Selection Design Trial | 2 | 59 | 73.1 (40.9–85.9 years old) | 24M 35F |
Stage IIIB, Stage IV | Smoker Status | N/A | Carboplatin, Erlotinib, Paclitaxel |
| Wu et al. (2020) | NCT01982955 | China, Italy, Malaysia, Singapore, South Korea Spain, Taiwan | Open-label, randomized, Phase 1b/2 study | 5 | 88 | N/A | 36M 52F |
Advanced | N/A | N/A | Carboplatin, Cisplatin, Gefitinib, Pemetrexed, Tepotinib, |
| Umsawasdi et al. (1989) | N/A | N/A | Randomised Study | 2 | 102 | 56.5 (33–78 years old) | 71M 31F |
Stage III | N/A | N/A | Cisplatin, Cyclophosphamide, Doxorubicin |
| Cortot et al. (2020) | NCT01763671 | France | Double-arm, Randomised, Open-label, Multicentre, Phase III Clinical Trial | 2 | 166 | 59.7 (18.6–81.8 years old) | 120M 46F |
Stage III, Stage IV | Smoker Status | N/A | Bevacizumab, Docetaxel, Paclitaxel |
| AstraZeneca (2021) | NCT01933932 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Turkey, Ukraine, United Kingdom, United States | A Phase III, Double-Blind, Randomised, Placebo-Controlled Study | 2 | 510 | 61.4 (S.D.: 8.3) | 303M 207F |
Stage IIIB, Stage IV | N/A | N/A | Docetaxel, Selumetinib |
| Johnson et al. (2004) | N/A | United States | Randomized Phase II Study | 3 | 99 | ≥18 years old | 60M 39F |
Stage IIIB, Stage IV | N/A | Dose | Bevacizumab, Carboplatin, Paclitaxel |
| Eli Lilly and Company (2022) | NCT00981058 | Australia, Austria, Belgium, Brazil, Canada, Croatia, France, Germany, Greece, Hungary, Italy, South Korea, Philippines, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, United Kingdom, United States | Multinational, Randomized, Multicenter, Open-label, Phase III Study | 2 | 1093 | 62 (32–86 years old) | 908M 185F |
Stage IIIB, Stage IV | Smoker Status | N/A | Cisplatin, Gemcitabine, Necitumumab |
| Eli Lilly and Company (2021) | NCT00982111 | Australia, Austria, Belgium, Brazil, Canada, Croatia, France, Germany, Greece, Hungary, Italy, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, United Kingdom, United States | Multinational, Randomized, Multicenter, Open-label Phase III Study | 2 | 633 | 61 (26–88 years old) | 424M 209F |
Stage IIIB, Stage IV | Smoker Status | N/A | Cisplatin, Pemetrexed, Necitumumab |
| Eli Lilly and Company (2019b) | NCT01769391 | Germany, South Korea, Mexico, Poland, Russia, United States | Randomized, Multicenter, Open-Label, Phase II Study | 2 | 167 | 65.3 | 131M 36F |
Stage IV | N/A | N/A | Carboplatin, Paclitaxel, Necitumumab |